One-time treatment is indicated to prevent long-term side effects of cancer radiotherapy

A new study has shown that a simple one-time treatment is able to prevent long-term side effects of cancer radiotherapy.

There are about 2 million of them those who survived cancer in the UK, and many are facing premature memory loss and the rapid onset of various diseases resembling premature aging, from which, unfortunately, there is no cure. It is thought to be caused by the side effects of toxic chemotherapy and radiotherapy cancers that are aimed at treating cancer cells but can also damage normal cells.

The researchers wanted to know if they could prevent such devastating effects of cancer treatment by short-term treatment with senolytics, a class of drugs that specifically eliminate damaged cells due to cancer treatment, and tested the idea on mice.

They found that animals receiving senolithic drugs shortly after radiation therapy did not have premature aging, and animals treated after they began to suffer from premature aging also improved their health.

Dr. Satomi Miwa, Professor of Translational Biology of Aging, University of Newcastle, is conducting a study published in eLifesays that “an increasing number of people are being successfully treated for cancer, and survival rates from many types of cancer are high. People who have beaten cancer may start looking forward to their new life again, but only if it does not affect their quality of life. Unfortunately, at the moment this is so. However, our new study shows that there is a way to prevent any long-term side effects and reduce the risk of cancer recurrence. ”

Senals

Senolithics are an exciting development in the biology of aging because drugs kill aging cells by targeting their survival mechanisms that are lacking in normal cells. They have been shown to delay or in some cases cure age-related diseases or disabilities in mice.

Dozens of clinical trials are currently being conducted or registered in the United States using various senolytic drugs in humans against conditions such as pulmonary fibrosis (pulmonary fibrosis), diabetic kidney disease and osteoarthritis.

The group intends to continue research, as Dr Miva explains: “We want to test our approach in specific types of cancer and move on to clinical conditions as soon as possible. We are particularly interested in those who have experienced a brain tumor in childhood as they are the most affected group of people suffering from long-term side effects from cancer treatment ”.

Research provides new hope for people who receive cancer therapies to ensure a better quality of life for the rest of your life.